Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
-
161por Mohamed Hussein, Aliae A. R., Ibrahim, Islam H., Mahmoud, Islam A., Amary, Marwa, Sayad, Reem“…Clinical trials of all three vaccines authorized for use in the UK (Pfizer–BioNTech, Oxford–AstraZeneca, and Moderna) have reported high vaccine efficacy. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
162por Westrop, Samantha J, Whitaker, Heather J, Powell, Annabel A, Power, Linda, Whillock, Corinne, Campbell, Helen, Simmons, Ruth, Warrener, Lenesha, Ramsay, Mary E, Ladhani, Shamez N, Brown, Kevin E, Amirthalingam, Gayatri“…METHODS: SARS-CoV-2 infection-naïve and previously-infected adults receiving ChAd-BNT (ChAdOx1 nCoV-19, AstraZeneca followed by BNT162b2, Pfizer-BioNTech) or BNT-ChAd as part of the UK national immunisation programme provided blood samples at 30 days and 12 weeks after their second dose. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
163por Graf, Anneke, Armeni, Eleni, Dickinson, Louise, Stubbs, Matthew, Craven, Brian, Srirangalingam, Umasuthan, Chung, Teng-Teng“…SUMMARY: Rare cases of vaccine-induced Immune thrombocytopenia and thrombosis (VITT) are being identified after vaccination with the SARS-CoV-2 Oxford–AstraZeneca vaccination. We report on two such patients with associated adrenal involvement, which is now being recognised. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
164“…Conclusions: Findings of the present study support the safety of the Oxford/AstraZeneca COVID-19 vaccine among HCWs in Saudi Arabia. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
165por Diogo, Patrícia, Correia, Gil, Martins, João B., Soares, Rui, Palma, Paulo J., Santos, João Miguel, Gonçalves, Teresa“…The ChAdOx1 nCoV-19 vector vaccine (Vaxzevria, AstraZeneca, Cambridge, UK) was developed at Oxford University and is considered safe for the administration in lactating mothers. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
166“…A 57-year-old man presented to the outpatient clinic with tremor, palpitations, weight loss and fatigue 1 week after receiving the first dose of the Oxford-AstraZeneca SARS-CoV-2 vaccine (ChAdOx1 nCoV-19). Laboratory studies showed a suppressed TSH with elevated total and free T4. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
167por Leys, Ynolde E., Nwokocha, Magdalene, Walker, Jerome P., Butterfield, Tiffany R., Frater, Velesha D., Thompson, Tamara K., Anderson, Mark, Cloherty, Gavin A., Anzinger, Joshua J.“…The Caribbean region is lacking an assessment of the antibody response and side effects experienced after AstraZeneca COVID-19 vaccination (AZD1222). We examined severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) IgG levels and report the side effects noted in a Jamaican population after AZD1222 vaccination. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
168“…We report the first case of IMNM two weeks after vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine. There was a probable temporal relationship between the COVID-19 vaccination and the development of IMNM due to lack of known causative factors for IMNM. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
169por Khan, Raveed, Albert, Rachel, Awe, Leann, De Four, Renee, Francois, Tichad, Hinds, Tahirah, Kellman, Avery, Maharaj, Kelsey, Mahon, Renea, Pierre, Chanel, Ramai, Alana, Baksh, Rameez“…The mean knowledge score about the AstraZeneca vaccine was 16.28 (SD = 2.28) out of 19 with an overall correct response rate of 79%. 30.4% of participants had a good attitude score and 59.7% had a positive perception toward the AstraZeneca vaccine. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
170
-
171por Chauhan, Sanshriti, Meshram, Hari Shankar, Kute, Vivek, Patel, Himanshu, Banerjee, Subho, Engineer, Divyesh, Deshmukh, Sandeep, Dave, RuchirEnlace del recurso
Publicado 2021
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
172por Meshram, Hari Shankar, Kute, Vivek B., Shah, Nauka, Chauhan, Sanshriti, Navadiya, Vijay V., Patel, Ansy H., Patel, Himanshu V., Engineer, Divyesh, Banerjee, Subho, Rizvi, Jamal, Mishra, Vineet V.Enlace del recurso
Publicado 2021
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
173por Al Rawahi, Bader, BaTaher, Hashem, Jaffer, Zoheb, Al‐Balushi, Aya, Al‐Mazrouqi, Asma, Al‐Balushi, NoofEnlace del recurso
Publicado 2021
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
174“…PURPOSE: The Oxford–AstraZeneca is one of COVID-19 vaccine which is expected to be mass-produced and plays a critical role in controlling the pandemic that the globe faced. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
175“…Our patient was a 48-year-old man who presented with frank haematuria, a widespread petechial rash, and headaches, 2 weeks after receiving the first dose of the Oxford AstraZeneca ChAdOx1 nCoV-19 vaccine. He had a platelet count of 14×10(9)/L and an extensive cerebral venous sinus thrombosis (CVST) with subarachnoid haemorrhage on imaging. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
176“…Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
177“…We describe a patient who developed bilateral oculomotor nerve palsy, ataxia, facial diplegia and lower limb weakness 2 weeks post-Oxford-AstraZeneca SARS-CoV2 vaccination, consistent with Miller-Fisher syndrome (MFS) and Guillain-Barre syndrome (GBS) overlap syndrome. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
178por Kaura, Amit, Trickey, Adam, Shah, Anoop S V, Benedetto, Umberto, Glampson, Ben, Mulla, Abdulrahim, Mercuri, Luca, Gautama, Sanjay, Costelloe, Ceire E, Goodman, Ian, Redhead, Julian, Saravanakumar, Kavitha, Mayer, Erik, Mayet, Jamil“…We compared the effectiveness of a single dose strategy of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines against SARS-CoV-2 infection across all age groups and over an extended follow-up period. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
179por Farias, Jessica Pires, da Silva, Patrícia de Souza, Fogaça, Mayanna Moreira Costa, Santana, Itana Vivian Rocha, Luiz, Wilson Barros, Birbrair, Alexander, Amorim, Jaime Henrique“…Immunological profiles were defined as individuals with or without previous SARS-CoV-2 infection who received at least one vaccine dose in the immunization regimens of AstraZeneca, CoronaVac, or CoronaVac plus a booster shot with Pfizer. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
180por Rosero-Bixby, Luis“…BACKGROUND: The Costa Rican COVID-19 vaccination program has used Pfizer-BioNTech and Oxford-AstraZeneca vaccines. Real-world estimates of the effectiveness of these vaccines to prevent hospitalizations range from 90%-98% for two doses and from 70%-91% for a single dose. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto